Garshick, Chiara Giannarelli, Ira J
National Prescribing Service (Australia)
Step 5: Select and clean your injection site Choose from one of three primary subcutaneous injection sites: the abdomen (most common), the front of the thigh, or the back of the upper arm
The oral formulation (Rybelsus) uses a sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) absorption enhancer for oral bioavailability
The GLP-1 class of drugs isn't recommended if you have a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia, or a history of pancreatitis
Other concerning symptoms include: Signs of dehydration (decreased urination, dizziness, extreme thirst) Persistent diarrhea lasting more than 48 hours Blood in stool or vomit Unexplained weight loss beyond expected therapeutic effects Severe constipation unresponsive to standard measures New or worsening heartburn or reflux symptoms Symptoms of gallbladder disease (right upper abdominal pain, especially after meals, fever, or jaundice) Signs of possible bowel obstruction or ileus (severe abdominal distension, inability to pass gas or stool) Before starting digestive enzyme supplements or any over-the-counter products, patients should discuss this decision with their healthcare provider or pharmacist